ALEXIS Biochemicals: Reveromycin A

ALX-380-216

Revised 20-Jun-08

Reveromycin A
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Cell Cycle Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-216-MC01		0.1 mg	150.00 USD
ALX-380-216-MC25		0.25 mg	320.00 USD

Product Specification

SEQUENCE:	134615-37-5
FORMULA:	C₃₆H₅₂O₁₁
MW:	660.8
SOURCE/HOST:	Isolated from Streptomyces sp. MST-AS5344.
PURITY:	≥99% (HPLC)
APPEARANCE:	White to tan solid.
SOLUBILITY:	Soluble in ethyl acetate, 100% ethanol, methanol, dimethyl formamide or DMSO.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Unstable in acidic conditions.

Product Description

Antibiotic. Dominant analog of the reveromycin complex. Inhibitor of the mitogenic activity of epidermal growth factor (EGF). G1 phase cell cycle inhibitor, selectively inhibiting isoleucyl-tRNA synthetase. Displays antiproliferative as well as potent antifungal activity. Induces apoptosis in osteoclasts thus inhibiting bone resorption.

Product Specific Literature References

Reveromycins, new inhibitors of eukaryotic cell growth. I. Producing organism, fermentation, isolation and physico-chemical properties: H. Takahashi, et al.; J. Antibiot. (Tokyo) 45, 1409 (1992) Abstract
Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities: H. Takahashi, et al.; J. Antibiot. (Tokyo) 45, 1414 (1992) Abstract
Chemical modification of reveromycin A and its biological activities: T. Shimizu, et al.; Bioorg. Med. Chem. Lett. 12, 3363 (2002) Abstract
Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G1-specific inhibitor Reveromycin A: Y. Miyamoto, et al.; J. Biol. Chem. 277, 28810 (2002) Abstract; Full Text
Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity: H. Muguruma, et al.; Clin. Cancer Res. 11, 8822 (2005) Abstract; Full Text
Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts: J.T. Woo, et al.; PNAS 103, 4729 (2006) Abstract; Full Text
Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone: S. Sone and S. Yano; Cancer Metastasis Rev. 26, 685 (2007) Abstract
Regulation of osteoclast polarization: N. Takahashi, et al.; Odontology 95, 1 (2007), (Review) Abstract

Further Categories Containing This Product:

Antibiotics - Apoptosis Inducers & Inhibitors • Cell Cycle Blockers & Inhibitors / Related Products • Bone Metabolism Other Products • EGFR Kinase Inhibitors • Antibiotics - Antifungal

another CS2 website

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.